Gland Pharma Ltd

Gland Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gland Pharma Ltd

₹ 2,380 0.09%
24 Jul - close price
glandpharma.com BSE: 543245 NSE: GLAND
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Key Points

Product Portfolio:[1]
The company is one of the largest and fastest-growing injectable-focused companies, which provides 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas.[2]

Website BSE NSE
  • Market Cap ₹ 39,260 Cr.
  • Current Price ₹ 2,380
  • High / Low ₹ 2,574 / 1,574
  • Stock P/E 37.6
  • Book Value ₹ 629
  • Dividend Yield 0.84 %
  • ROCE 15.1 %
  • ROE 10.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.1%

Cons

  • Stock is trading at 3.79 times its book value
  • Company has a low return on equity of 9.30% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.09%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
785 1,209 1,373 1,545 1,537 1,402 1,406 1,384 1,425 1,506 1,487 1,695 1,743
617 915 1,049 1,189 1,179 1,137 1,109 1,024 1,077 1,138 1,173 1,260 1,230
Operating Profit 168 294 324 356 359 264 297 360 348 368 314 435 513
OPM % 21% 24% 24% 23% 23% 19% 21% 26% 24% 24% 21% 26% 29%
-18 38 53 37 42 51 60 58 44 58 84 39 111
Interest 2 5 6 5 10 6 6 23 7 12 8 4 10
Depreciation 38 65 81 105 93 92 94 96 96 101 106 108 109
Profit before tax 111 261 290 283 298 218 257 299 288 313 284 362 506
Tax % 29% 26% 33% 32% 35% 34% 36% 32% 35% 31% 35% 28% 28%
79 194 194 192 192 144 164 205 187 215 184 261 367
EPS in Rs 4.78 11.79 11.78 11.65 11.68 8.73 9.93 12.42 11.32 13.08 11.15 15.87 22.26
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,633 3,463 4,401 3,625 5,665 5,616 6,431
1,678 2,161 2,890 2,600 4,332 4,348 4,801
Operating Profit 955 1,302 1,510 1,025 1,333 1,269 1,630
OPM % 36% 38% 34% 28% 24% 23% 25%
139 135 224 184 170 214 292
Interest 7 3 5 7 26 42 33
Depreciation 95 99 110 147 345 378 424
Profit before tax 993 1,335 1,619 1,055 1,133 1,063 1,465
Tax % 22% 25% 25% 26% 32% 34% 30%
773 997 1,212 781 772 699 1,027
EPS in Rs 49.88 60.94 73.75 47.42 46.90 42.40 62.35
Dividend Payout % 0% 0% 0% 0% 43% 42% 32%
Compounded Sales Growth
10 Years: %
5 Years: 13%
3 Years: 21%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: 1%
3 Years: 8%
TTM: 50%
Stock Price CAGR
10 Years: %
5 Years: -10%
3 Years: 25%
1 Year: 18%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 9%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 16 16 16 16 16 16 16
Reserves 3,631 5,887 7,141 7,942 8,707 9,134 10,341
5 5 5 4 372 314 284
435 588 671 814 1,515 1,708 1,869
Total Liabilities 4,086 6,496 7,834 8,778 10,611 11,173 12,511
968 954 1,502 1,571 3,947 4,147 4,492
CWIP 188 338 191 177 238 151 342
Investments 0 0 155 0 0 0 0
2,929 5,204 5,986 7,030 6,426 6,875 7,676
Total Assets 4,086 6,496 7,834 8,778 10,611 11,173 12,511

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
701 605 791 364 997 915 1,031
-761 -1,520 -999 1,211 -1,749 1,718 138
-7 1,238 35 15 -799 -433 -417
Net Cash Flow -67 323 -174 1,590 -1,552 2,199 752
Free Cash Flow 530 377 269 141 599 521 538
CFO/OP 99% 70% 79% 66% 98% 100% 91%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 83 71 99 88 100 99 107
Inventory Days 250 312 205 421 278 294 284
Days Payable 82 97 80 127 129 143 136
Cash Conversion Cycle 251 286 225 382 250 250 255
Working Capital Days 161 169 168 242 155 173 145
ROCE % 28% 25% 15% 14% 12% 15%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Expenses as % of Revenue
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDA Approvals (US)
count
Cumulative ANDA Filings (US)
count
US Market Revenue (Gland base business)
INR Mn ・Standalone data
US as % of Group Revenue
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

8 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
57.86% 57.86% 57.86% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.77%
4.91% 4.05% 3.59% 6.88% 4.48% 5.04% 6.90% 7.39% 7.90% 7.58% 7.29% 8.74%
22.45% 24.17% 25.23% 32.83% 35.37% 34.80% 33.27% 32.86% 32.63% 32.99% 33.36% 30.44%
14.78% 13.93% 13.32% 8.46% 8.33% 8.33% 8.00% 7.93% 7.63% 7.62% 7.52% 9.06%
No. of Shareholders 1,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,57891,5001,08,266

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls